Introduction
STAT3 (signal transducers and activators of transcription 3) is an oncogene and plays very important roles in cell proliferation, apoptosis, and metastasis [1] . Despite its important functions in cancer, so far, there are few effective therapeutic methods to inhibit STAT3 in the clinic [2] . A number of studies have shown that STAT3 is constitutively activated in many types of cancers including oral cancer by phosphorylation and dimerization [3, 4] . Many inhibitors have been developed to block the activation of STAT3. However, STAT3 can be activated by diverse receptors, which may attenuate the efficacy of STAT3 activation inhibitors. In addition, unphosphorylated STAT3 can promote cancer progression by enhancing the expression of oncogene RAS and Met [5] . Therefore, suppression of STAT3 expression may be an efficient way for cancer treatment.
STAT3 gene consists of 24 exons. Alternative splicing of exon 23 generates two isoforms, STAT3α and STAT3β. STAT3α encodes full-length oncogenic STAT3 protein (89kDa), whereas STAT3β encodes a truncated protein (80 kDa) [6] . In contrast to STAT3α, STAT3β plays negative roles in tumorigenesis [7] ( Figure 1A ). The lack of STAT3β contributes to enhanced inflammation and earlier tumor initiation [8] . The expression of STAT3β is strongly correlated with longer survival and less recurrence in esophageal squamous cell carcinoma (ESCC) patients. Moreover, STAT3β can suppress chemoresistance and cancer stemness of ESCC cells by blocking the transcriptional activity of STAT3α [9] . Inhibiting STAT3α expression led to tumor regression [10] .
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However, the mechanism of regulating alternative splicing of STAT3 exon 23 is unclear.
Alternative splicing of pre-mRNA is mainly regulated by splicing factor. PCBP1 [poly(rC)-binding protein 1, or hnRNP E1], is a tumor-suppressive splicing factor and regulates the process of pre-mRNA, mRNA stability, and translation {summarized in Ref. [11] [12]}. It also functions as a chaperone for the delivery of iron in cell [13] . Overexpression of PCBP1 suppresses the tumorigenicity of cancer cells, such as prostate cancer [14, 15] , colon cancer [16] , gastric cancer [17] , ovarian cancer [18] , and thyroid carcinoma cells [19] . In the present study, we discovered that PCBP1 is the key splicing factor that regulates alternative splicing of STAT3 exon 23 and promotes the switch from oncogenic isoform STAT3α to tumor-suppressive isoform STAT3β. Our results pave the way for finding new anti-STAT3 methods for cancer treatment.
Results

Regulatory motifs in STAT3 exon 23
The regulatory mechanisms of alternative splicing of STAT3 exon 23 in cancers are unknown. Oral squamous cell carcinoma (OSCC) is the most common type of head and neck squamous cell carcinoma. We constructed a human STAT3 minigene, including exon 22, intron 22 and exon 23 ( Figure 1B) . Then, we made serial mutations from nt 1 to nt 92 of exon 23 to screen potential regulatory motifs for controlling alternative splicing of exon 23. RT-PCR result showed that all mutants (mt1 to mt4) between proximal and distal splice sites almost totally lost the usage of distal splice site (short product), indicating that these sequences contain regulatory motifs required for the expression of STAT3β. In contrast, the mutants downstream of distal splice site have no effect on the alternative splicing of exon 23, except mutant mt7 ( Figure 1C ). Figure 1D, Figure S1 , S2). We found that PCBP1 is the one that most significantly decreases the ratio of STAT3α vs STAT3β isoform compared with control (fold change>1.5, P<0.01) ( Figure 1D , 1E, Figure S1B ). PCBP1 was reported as a tumor-suppressive gene [16] . Our results suggested that PCBP1 increases the level of STAT3β, which is correlated with its tumor-suppressive function.
In addition, we found that the ratio of STAT3α /β and the RNA level of STAT3α expression in normal primary cultured oral gingival epithelial cells were significantly lower than those in oral cancer cells ( Figure 1F ). The protein levels of PCBP1 in normal cells were significantly higher than those in the oral cancer cell lines, CAL 27 and SCC-9. On the contrary, cancer cells have significantly higher level of STAT3α protein than normal cells ( Figure 1G ). These results indicate that the expression of STAT3α may be inhibited by the high level of PCBP1 in normal cells.
PCBP1 interacts with an exonic splicing suppressor in exon 23
PCBP1 can interact with splicing silencing elements in alternative exons and suppresses their inclusion. We hypothesized that PCBP1 binds to an exonic splicing suppressor (ESS) in exon 23 and inhibits the usage of proximal splice site of exon 23 and the expression of STAT3α. Sequence analysis suggested that the original sequence of mt4, "UCCCCCCG", is similar to known C-rich binding motifs of PCBP1 [20] (Figure 1B) . We synthesized biotin labeled wild-type or mutant ESS RNA and performed pulldown assay with 293 total extract. As expected, PCBP1 can bind to wild-type ESS (called wt4), not mutant ESS (mt4), indicating that PCBP1 may bind to "UCCCCCCG" and promote the usage of distal 3' splice site of exon 23 and the expression of STAT3β (Figure 2A ). 
PCBP1 represses the expression of STAT3α in oral squamous cell carcinoma cells
STAT3 is involved in the tumorigenesis of OSCC. We wonder whether overexpression of PCBP1 can reduce the expression of STAT3, especially STAT3α, in OSCC cells. We established stable overexpression of PCBP1 in CAL 27 and SCC-9 cells, and found that overexpression of PCBP1 significantly reduced the ratios of STAT3α vs β and the levels of STAT3α by RT-PCR analysis ( Figure 2B ). Western blot also showed that the expression of STAT3α and phosphorylation of STAT3α decreased significantly upon overexpression of PCBP1 ( Figure 2C ). In contrast, in normal cells, knockdown of PCBP1 significantly increased the ratio of STAT3α vs β and the RNA levels of STAT3α compared with control group ( Figure 2D ), as well as the protein level of STAT3α and phosphorylation of STAT3α ( Figure 2D ). In addition, we found that mt4 abolished PCBP1's inhibitory effects on STAT3α expression ( Figure S5 ). These results demonstrate that PCBP1 represses STAT3α expression.
STAT3 plays key roles in the initiation of tumorigenesis by promoting the expression of oncogenic targets, including Bcl-xL and survivin. Bcl-xL has central roles in suppressing apoptosis. Survivin can also block apoptosis. We found that the transcription levels of survivin, and Bcl-xL were reduced in CAL 27 and SCC-9 cells with PCBP1 overexpression ( Figure 2E ). These results further confirmed PCBP1 repressed the expression of STAT3α.
PCBP1 inhibits the proliferation and colony formation of OSCC cells
PCBP1 has been considered as a tumor suppressor. We found that overexpression of PCBP1 significantly inhibited the growth of CAL 27 and SCC-9 cells (Figure 3A-B) . In addition, cells with PCBP1 overexpression showed significantly less colonies compared with control cells (Figure 3C-D) . In line with these findings, knockdown of PCBP1 promoted cell proliferation in both CAL 27 and SCC-9 cancer cells ( Figure S4C and S4D) . Moreover, knockdown of PCBP1 increased the ratio of STAT3α vs STAT3β and the expression of STAT3α protein in both CAL 27 and SCC-9 cancer cells ( Figure S4A and S4B). These results suggested that PCBP1 also acts as a tumor suppressor and inhibits the proliferation of oral cancer cells.
STAT3α rescues the cell proliferation and colony formation in PCBP1 overexpressed OSCC cells
To understand whether PCBP1 inhibits cancer cell proliferation through suppressing STAT3α expression, we established cell lines in CAL 27 as following: overexpression of PCBP1, overexpression of both PCBP1 and STAT3α, overexpression of STAT3α, or vector control. Western blot analysis confirmed the overexpression of T7 tagged PCBP1 and/or GFP tagged STAT3α ( Figure 3G ). Cell proliferation assay revealed that overexpression of STAT3α almost completely rescued cell growth and colony formation in PCBP1-overexpressed cells ( Figure 3E-I) . Moreover, overexpression of STAT3α can restore the expression of Bcl-xL and survivin in PCBP1-overexpressed cells ( Figure 3J ). Similar results were also observed in SCC-9 cells ( Figure S3 ). These results demonstrated that PCBP1 inhibits cancer cell proliferation through inhibiting the expression of oncogene STAT3α.
STAT3α partially rescues the tumorigenesis in PCBP1 overexpressed OSCC cells
To understand whether PCBP1 inhibits the tumorigenesis of cancer cells through suppressing STAT3α expression. We also inoculated previous CAL 27 cells with overexpression of PCBP1, overexpression of both PCBP1 and STAT3α, overexpression of STAT3α, or vector control into nude mice. We found that overexpression PCBP1 significantly inhibited tumorigenesis. Co-overexpression of STAT3α can partially rescue tumor formation in PCBP1-overexpressed cells ( Figure 3K-M) . These results demonstrated that PCBP1 suppresses cancer cell tumorigenesis partially through inhibiting the expression of oncogene STAT3α.
PCBP1 inhibits the expression of STAT3α and cell proliferation in breast cancer cells
We also analyzed the functions of PCBP1 in MCF-7, a breast cancer cell line. We found that overexpression of PCBP1 significantly reduced the cell proliferation of MCF-7 cells (Figure 4A-B) , decreased the ratio of STAT3α vs STAT3β isoform and the protein level of STAT3α ( Figure 4C-D) , and suppressed the expression of Bcl-xL and survivin compared with controls ( Figure 4E ). These results suggested that PCBP1-dependent STAT3α/STAT3β regulation may be a common activity in tumor cells.
STAT3β inhibits cell proliferation and colony formation in OSCC cells, and the expression of Bcl-xL and survivin.
To further understand the functions of STAT3β in OSCC, we overexpressed STAT3β in CAL 27 or SCC-9 cells. Overexpression of STAT3β significantly reduced cell proliferation and colony formation compared with controls ( Figure 5A-C, 5E-F) . The increased cell proliferation induced by knockdown of PCBP1 could be overcome by overexpression of STAT3β ( Figure 5G-I) . In addition, in contrast to STAT3α, we discovered that overexpression of STAT3β suppressed the expression of Bcl-xL and survivin ( Figure 5D ). These results suggested that STAT3β functions as a tumor suppressor in OSCC. 
Discussion
A number of inhibitors have been developed to block the oncogenic activation of STAT3 [2] . STAT3β shared coiled-coil domain (CCD), DNA-binding domain (DBD) and SH2 domain with STAT3α. Therefore, small molecule inhibitors targeting these domains will block both STAT3α's and STAT3β's functions. Although STAT3β is missing the transactivation domain and generally considered as a dominant negative form, it can play unique functions and rescue the embryonic lethality of a STAT3-null mutation mice [21] . So, the inhibitors targeting STAT3 may cause unexpected side effects due to repressing the function of STAT3β. STAT3β has been found to be a tumor suppressor [7, 8] . In line with previous studies, we also found that STAT3β represses the cell proliferation and colony formation of OSCC cells. To reduce side effects and enhance anti-tumor capability, it may be useful to develop novel methods to promote the shift from STAT3α to STAT3β by modulating the alternative splicing of exon 23 in cancer cells. Zammarchi et al. have shown that antisense oligonucleotide against proximal splice site of exon 23 can drive the shift from STAT3α to STAT3β and suppress tumor formation [10] . Our results demonstrated that increasing the expression of PCBP1 also promotes the shift from STAT3α to STAT3β and inhibits cell proliferation in both oral cancer cells and breast cancer cells, and may be a novel anti-tumor method.
In the screening experiment ( Figure 1B-C) , we discovered that all mutants between proximal and distal splice sites abolished the expression of STAT3β. In addition, mt7, a downstream mutant, also reduced the expression of STAT3β. By using SFmap online program, we found that splicing factor QKI might bind to the wild-type sequence of mt7 through an AAUAAU motif. Interestingly, QKI was considered as a tumor suppressor [22] . Therefore, QKI may increase the expression of STAT3β by binding to AAUAAU motif. However, we found that overexpression of QKI-6 couldn't increase STAT3β expression ( Figure S1 ). QKI has three isoforms (QKI-5, QKI-6, and QKI-7). Further experiments are required to clarify the functions of QKI isoforms in the alternative splicing of STAT3 exon 23.
Head and neck squamous cell carcinoma is the sixth most common cancer in the world. Oral squamous cell carcinoma (OSCC) is the most common type of head and neck squamous cell carcinoma. STAT3 is significantly upregulated and constitutively activated in head and neck squamous cell carcinoma [23] . Constitutive activation of STAT3 was also found to be an early event in head and neck carcinogenesis [24] . A p-STAT3 inhibitor significantly delayed tumorigenesis in a spontaneous head and neck squamous cell carcinoma mouse model [23] , suggesting STAT3 can be a therapeutic target for OSCC. However, like other cancers, there are few effective therapeutic methods to inhibit STAT3 in the treatment of OSCC. In this study, we found that overexpression of PCBP1 inhibited the expression of oncogenic STAT3α and repressed the cell proliferation of OCSS cells. Therefore, upregulation of PCBP1 may be a promising novel method to inhibit STAT3 in OSCC. In addition, we found that overexpression of PCBP1 also significantly repressed cell proliferation and decreased the expression of oncogenic STAT3α in breast cancer cell line, MCF-7. STAT3 is constitutively activated in more than 40% of breast cancer and plays key roles in cell proliferation, angiogenesis, apoptosis, and metastasis in breast cancer [25] . Our results may pave the way to novel options for the treatment of breast cancer or other types of cancer by upregulation of PCBP1.
Activation of STAT3 suppresses the expression of proapoptotic genes in cancer cells [26] . STAT3 also promotes the expression of anti-apoptotic genes, such as Bcl-xL and survivin. Bcl-xL is a member of the Bcl-2 family proteins, and plays central roles in suppressing apoptosis [27] . Survivin is a member of the inhibitor of apoptosis protein family, and could block apoptosis through suppressing activation of caspases [28] . It has been reported that overexpression of PCBP1 induced apoptosis by downregulating Bcl-2 [29] . Our results discovered that PCBP1 is also able to inhibit the expression of Bcl-xL and survivin induced by STAT3, suggesting a novel mechanism, by which PCBP1 induces apoptosis.
In conclusion, PCBP1 is the key splicing factor that regulates alternative splicing of STAT3 exon 23 and promotes the switch from oncogenic isoform STAT3α to tumor-suppressive isoform STAT3β. Our results may initiate new methods for anti-STAT3 treatment in cancers. 
Materials and Methods
Cell culture
Normal gingival epithelial cells were derived from gingival tissues of healthy donors and cultured in keratinocyte growth medium (KGM, Lonza, Switzerland) as described in our previous study [30] . HEK-293 cell and OSCC cell line CAL 27 cell were grown in Dulbecco's modified Eagle medium (DMEM; HyClone, USA) with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic (Gibco, USA). OSCC cell line SCC-9 cell was cultured in DMEM/F12 with 10% FBS and 1% antibiotic-antimycotic (Gibco, USA) and 1‰ hydrocortisone. MCF-7 cell, a breast cancer cell line, was grown in Eagle's Minimum Essential Medium (EMEM) (HyClone, USA) with 10% FBS and 1% antibiotic-antimycotic. Cell culture is maintained at 37°C in 5% CO2. All experimental protocols were approved by the Ethics Committee at the School of Stomatology in Wuhan University. The methods were performed in accordance with the approved guidelines.
Plasmids
Genomic DNA sequence from exon 22 to exon 23 of human STAT3 was amplified from the CAL 27 genome by primer 5' CGCTGCCCCATACCTGAAG AC 3' and 5' GGTTCAGCACCTTCACCATTATTTC 3'. The PCR product was further amplified by 5' GAATTCACCATGGCTGCCCCATACCTGAAGAC 3' and 5' GGATCCGGTTCAGCACCTTCACCATT ATTTC 3', and cloned into pEGFP-N1 at BamHI and EcoRI sites. The resulting minigene plasmid carried genomic sequence of STAT3 from exon 22 to exon 23. To map potential regulatory motifs, the sequence from nt 5 to 88 of exon 23 in minigene was serially mutated every 10 bases. The mutation was made by substituting a base by its complementary base every other base ( Figure 1B) . For STAT3α overexpression, the open reading frame of human STAT3α isoform was cloned into pLVX-IRES-PURO vector at NotI and SpeI sites. For STAT3β overexpression, the open reading frame of human STAT3β isoform was cloned into pLVX-IRES-PURO vector at NotI and SphI sites. The open reading frame of human PCPB1 was obtained from CAL 27 cells and fused with T7 tag, and then cloned into pLVX-IRES-Zsgreen vector at NotI and EcoRI sites. Plasmids expressing Flag tagged HuB, HuC, HuD, and QKI-6 were gifts from Dr. Thomas Tuschl (Addgene plasmid #65755, #65756, #65757, and #19891) [31] . Plasmid expressing Flag tagged FUS was a gift from Dr. Patrick Calsou (Addgene plasmid #60362) [32] . Plasmid expressing Flag tagged hnRNP F and hnRNP H1 were gifts from Dr. Mariano Garcia-Blanco (Addgene plasmid #21926 and #21925) [33] . Plasmid expressing Flag tagged hnRNP R was a gift from Dr. Markus Landthaler (Addgene plasmid #38067) [4] . Plasmid expressing Flag tagged SRm160 was a gift from Dr. Phillip Sharp (Addgene plasmid #11305) [34] . Plasmid expressing Flag tagged SF3B1 was a gift from Dr. Manoj Pillai (Addgene plasmid #82576) [35] . Plasmid expressing GFP tagged FOX1, NOVA1 and FOX2 were gifts from Dr. Nicolas Charlet-Berguerand (Addgene plasmid #63085, #61275 and #63086). Plasmid expressing GFP tagged RBM3 was a gift from Dr. Maria Alvarado-Kristensson (Addgene plasmid #87860) [36] . Plasmid expressing GFP tagged FLKSRP was a gift from Dr. Douglas Black (Addgene plasmid #23001) [37] . Plasmid expressing Myc tagged YBX1 was a gift from Dr. Thomas Tuschl (Addgene plasmid #19878) [38] . Plasmid expressing Myc tagged PSF was a gift from Dr. Benjamin Blencowe (Addgene plasmid #35183) [39] . Plasmid expressing Flag tagged SC35 was a gift from Dr. Zhi-Ming Zheng. T7 tagged PTBP1, hnRNP A1, and hnRNP L expressing plasmids were made in our previous publications [30, 40, 41] . HnRNP K gene was amplified from CAL 27 cells by 5' TAATAACTGATTGGTGTGCCCG 3' and 5' AAACTTTCCAGAATACTGCTTCACAC and fused with T7 tag, and then cloned into pLVX-IRES-PURO vector at NotI and SpeI sites.
RNAi and transfection
The sequence of human PCBP1 siRNA is 5' GAACCAGGUGGCAAGACAA 3', and was synthesized by Genepharma (Shanghai, China). Primary normal oral mucosal epithelial cells were transfected with 20 nM siRNA in the presence of Lipofectamine 3000 (Invitrogen, USA) according to the manufacturer's instructions. After 48 hours, cells were transfected again.
For plasmid transfection, 293 cells were transfected with 1 µg T7 tagged PCBP1 expression or empty vector plasmid in the presence of Lipofectamine 3000 24 hours later after the cells adhered to the wall. Total protein and RNA were collected 48 hours later.
CAL 27 cell and SCC-9 cell were stably transfected with T7-tagged PCBP1 expression lentivirus, STAT3-GFP expression lentivirus, empty control lentivirus and/or GFP expression control lentivirus in the presence of Lipofectamine 3000.
Western blot
Total protein samples were lysed with 2 × SDS sample buffer, and then denatured proteins were loaded onto 10% SDS-PAGE gel, transferred to a nitrocellulose membrane, and blocked by 5% non-fat milk dissolved in TBST (Tris-buffered saline, 0.1% Tween 20) . The protein samples were analyzed by the following antibodies: mouse anti-PCBP1 (Origene, USA), mouse anti-STAT3 (no. 610189; BD Biosciences, USA), mouse anti-phospho-specific STAT3 (pY705, Santa Cruz Biotechnology, USA), mouse anti-GAPDH (Santa Cruz Biotechnology), mouse anti-GFP (Santa Cruz Biotechnology), mouse anti-Flag (Sigma-Aldrich, USA), mouse anti-Myc (Yeasen, Shanghai, China) or mouse anti-T7 (Novagen, USA).
Reverse transcriptase PCR (RT-PCR)
Total RNA was extracted using the Total RNA Miniprep Kit (AxyPrep, USA) according to the manufacturer's protocol. Isolated RNA was reversely transcribed by using random hexamers (Promega, USA) and Moloney Murine Leukemia Virus Reverse Transcriptase (MMLV, Promega, USA), and amplified with Taq DNA polymerase (Takara, Japan) as described by the manufacturer. The primer pairs were as follows: 5' CGCTGCCCCATACCTGAAGAC 3' and 5′ GCTCCTCGCCCTTGCTCACCA 3′ for exogenous exon 23 alternative splicing detection in the minigene; 5' ATCGGCAGGTCAATGGTATTGC 3′ and 5' AAGGAGGAGGCATTCGGAAAGTA 3′ for endogenous STAT3α; 5' CCAAACTGCATCAATG AATGGTGT 3′ and for endogenous STAT3β; 5' CAGTGCGGCTCCCTGATTG 3′ and 5' CCTCTGG AGAGCTGGAGTCAATTC 3′ for PCBP1; 5′ GTGA ATTTTTGAAACTGGACAG 3′ and 5′ CCTTTCCTAA GACATTGCTAAG 3′ for survivin; 5′ ACCCCAGG GACAGCATATCA 3′ and 5′ TGCGATCCGACTCA CCAATA 3′ for Bcl-xL; 5′ GTCATCAATGGAAAT CCCATCACC 3′ and 5′ TGAGTCCTTCCACGA TACCAAA 3′ for GAPDH.
RNA pull-down assay
Biotin-labeled STAT3 RNA oligonucleotides wt-4 (5′ Biotin-CGAUGUCCCCCCGCACUUTT 3′ wild type), mt-4 (5′Biotin-CGAUGACGCGCGGCACUUTT 3' mutant, mutation was underlined), and PCBP1+ (5′ Biotin-CCUAUCCCUCUCCUAACUTT 3′, positive PCPB1 binding motif [42] ) were synthesized by Sangon Biotech (China). The total HEK 293 cell extract was prepared by using radioimmunoprecipitation assay (RIPA) buffer (Thermo scientific, USA). Five microliter biotin-labeled RNA oligonucleotide (40μM) was immobilized onto 100μl of NeutrAvidin beads (Pierce, USA). The bead-RNA complex was then incubated with total cell extract of HEK 293 cells in a 1× binding buffer (20mM Tris, 200mM NaCl, 6mM EDTA, 5mM potassium fluoride, 5mM β-glycerophosphate, 2μg/ml aprotinin, pH 7.5) at 4°C for 2h. The proteins associated with RNA were eluted by sodium dodecyl sulfate sample buffer and analyzed by using western blot.
Colony formation assay
One thousand cells were seeded into 60-mm cell culture dishes and cultured in complete medium for 10 days at 37°C. Then, cells were fixed with 4% paraformaldehyde and stained with crystal violet. The number of colonies (at least 50 cells/colony) was counted.
Tumor induction in nude mice
CAL 27 cells stably transfected with T7-PCBP1 expression lentivirus, STAT3-GFP expression lentivirus, empty control lentivirus and/or GFP expression control lentivirus were injected subcutaneously into nude mice (5 × 105 cells per mice, 5 mice per group). Tumor sizes were monitored every 3 days. Tumors were allowed to grow for 27 days and then the mice were sacrificed and tumors were dissected out and weighed. All methods of the animal studies were conducted in accordance with the relevant institutional guidelines.
Statistical analysis
All two-group statistical comparisons of means were calculated with student's t-test (Excel, Microsoft).
